Palbociclib and Letrozole in Advanced Breast Cancer

来曲唑 帕博西利布 医学 乳腺癌 内科学 肿瘤科 转移性乳腺癌 妇科 雌激素受体 癌症 三苯氧胺
作者
Richard S. Finn,Miguel Martín,Hope S. Rugo,Stephen E. Jones,Seock‐Ah Im,Karen A. Gelmon,Nadia Harbeck,Oleg Nikolaevich Lipatov,Janice Maria Walshe,Stacy Moulder,Eric Roland Gauthier,Dongrui Ray Lu,Sophia Randolph,Veronique C Dieras,Dennis J. Slamon
出处
期刊:The New England Journal of Medicine [Massachusetts Medical Society]
卷期号:375 (20): 1925-1936 被引量:3002
标识
DOI:10.1056/nejmoa1607303
摘要

BACKGROUND: A phase 2 study showed that progression-free survival was longer with palbociclib plus letrozole than with letrozole alone in the initial treatment of postmenopausal women with estrogen-receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer. We performed a phase 3 study that was designed to confirm and expand the efficacy and safety data for palbociclib plus letrozole for this indication. METHODS: In this double-blind study, we randomly assigned, in a 2:1 ratio, 666 postmenopausal women with ER-positive, HER2-negative breast cancer, who had not had prior treatment for advanced disease, to receive palbociclib plus letrozole or placebo plus letrozole. The primary end point was progression-free survival, as assessed by the investigators; secondary end points were overall survival, objective response, clinical benefit response, patient-reported outcomes, pharmacokinetic effects, and safety. RESULTS: The median progression-free survival was 24.8 months (95% confidence interval [CI], 22.1 to not estimable) in the palbociclib-letrozole group, as compared with 14.5 months (95% CI, 12.9 to 17.1) in the placebo-letrozole group (hazard ratio for disease progression or death, 0.58; 95% CI, 0.46 to 0.72; P<0.001). The most common grade 3 or 4 adverse events were neutropenia (occurring in 66.4% of the patients in the palbociclib-letrozole group vs. 1.4% in the placebo-letrozole group), leukopenia (24.8% vs. 0%), anemia (5.4% vs. 1.8%), and fatigue (1.8% vs. 0.5%). Febrile neutropenia was reported in 1.8% of patients in the palbociclib-letrozole group and in none of the patients in the placebo-letrozole group. Permanent discontinuation of any study treatment as a result of adverse events occurred in 43 patients (9.7%) in the palbociclib-letrozole group and in 13 patients (5.9%) in the placebo-letrozole group. CONCLUSIONS: Among patients with previously untreated ER-positive, HER2-negative advanced breast cancer, palbociclib combined with letrozole resulted in significantly longer progression-free survival than that with letrozole alone, although the rates of myelotoxic effects were higher with palbociclib-letrozole. (Funded by Pfizer; PALOMA-2 ClinicalTrials.gov number, NCT01740427 .).
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
刚刚
能干蜜蜂完成签到,获得积分10
刚刚
萨蒂恐龙完成签到 ,获得积分10
1秒前
nove999完成签到 ,获得积分0
1秒前
tutu发布了新的文献求助10
1秒前
2秒前
3秒前
3秒前
csd发布了新的文献求助10
4秒前
5秒前
如约而至发布了新的文献求助10
5秒前
斯多姆发布了新的文献求助10
6秒前
荼蘼发布了新的文献求助10
6秒前
AA发布了新的文献求助10
7秒前
7秒前
英姑的应助被科研通管家采纳,获得10
8秒前
上官若男的应助被科研通管家采纳,获得10
8秒前
8秒前
8秒前
李健的应助被科研通管家采纳,获得10
8秒前
张点心发布了新的文献求助10
8秒前
蓝天的应助被科研通管家采纳,获得10
8秒前
Liuyan的应助被科研通管家采纳,获得10
8秒前
Richard发布了新的文献求助10
8秒前
初景的应助被科研通管家采纳,获得20
9秒前
无极微光的应助被科研通管家采纳,获得20
9秒前
跳跃靖发布了新的文献求助10
9秒前
Maestro_S的应助被科研通管家采纳,获得10
9秒前
完美世界的应助被科研通管家采纳,获得10
9秒前
9秒前
大模型的应助被科研通管家采纳,获得10
9秒前
ding的应助被科研通管家采纳,获得10
9秒前
华无剑的应助被科研通管家采纳,获得10
10秒前
大模型的应助被科研通管家采纳,获得10
10秒前
hhjj完成签到,获得积分20
11秒前
xuwan完成签到,获得积分10
11秒前
脑洞疼的应助被卡卡584采纳,获得10
12秒前
12秒前
12秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
Resource Recovery Handbook 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8175157
求助须知:如何正确求助?哪些是违规求助? 9566975
关于积分的说明 21789458
捐赠科研通 7769647
什么是DOI,文献DOI怎么找? 3431836
关于科研通互助平台的介绍 2556078
邀请新用户注册赠送积分活动 2477241